darunavir continues to show staying power

[Guest guest]

Tibotec is so good at hyping their drug before and after approval. It is a good PI, but not as good as they say for people with heavy pretreatment history. I , and several people I know, have developed resistance to this protease in the presence of another active agent in a matter of 24 weeks or less. The side effects are a lot like Kaletra's also.

**********************

After 48 weeks of study, and 24 weeks in the real world, darunavir continues to show staying power

The recently-approved‘salvage’ protease inhibitor (PI), darunavir (Prezista), boosted by a small additional dose of ritonavir (Norvir) and in combination with an optimal background regimen, continues to show itself to be safe and potent, according to three studies presented last week to the Frontiers in Drug Development for Antiretroviral Therapies (DART) conference in Cancun, Mexico. At 48 weeks, a total of 45% of over 450 POWER 1, 2, and 3 participants had a plasma viral load below 50 copies/ml, with short- and longer-term side-effects and toxicities comparable to most first-line boosted PIs.

Read More >>

Regards, Vergelpowerusa dot org"What we think, or what we know, or what we believe is, in the end, of little consequence. The only consequence is what we do." - Ruskin